In vitro susceptibilities of Entamoeba histolytica to azithromycin, CP-63,956, erythromycin, and metronidazole.
Current therapy of Entamoeba histolytica infection requires use of multiple agents effective at different body sites, including the intestinal lumen, intestinal tissue, and liver. Azithromycin and CP-63,956, new extended-half-life macrolides which reach high levels in tissue, exhibit in vitro antiamebic activity at 18 or 48 h of incubation at concentrations comparable to that of erythromycin and slightly higher than that of metronidazole. Azithromycin and CP-63,956 have the potential to be useful therapeutic agents for all types of E. histolytica infection.
Ravdin
J I
JI
Department of Medicine, University of Virginia School of Medicine, Charlottesville 22908.
Skilogiannis
J
J
D000818:Animals; D000981:Antiprotozoal Agents / Q000494:pharmacology*; D017963:Azithromycin; D004748:Entamoeba histolytica / Q000187:drug effects*; D004917:Erythromycin / Q000031:analogs & derivatives* / Q000494:pharmacology*; D008795:Metronidazole / Q000494:pharmacology*; D013997:Time Factors
D000981:Antiprotozoal Agents; C060737:CP 63956; D008795:Metronidazole; D004917:Erythromycin; D017963:Azithromycin